Member Info for crumbs

Ray totally agree about CEPI and the delivery... it fits in with what they are looking for perfectly ... It's like scancell /team Notts and ticking every single box..... can't be being ignored it just can't be!

Again the amount of science in Coividty is just wow... it's beyond next-gen ImmunoBody... you have AvidiMaB in there a product with absolutely massive potential .... you now have the possibility of a stable for years DNA vax being delivered via a spay or microneedle patch.... that will include cancer vaccines!... no more electroporation issues ! Suck on that Inovio lol.... then the actual 'simple non-toxic peptide delivery' .... it could deliver all those mRNA vaxs too!... immense I hope it comes in-house and that that is part of the coming further Covidity updates....

Next ...moditope :)))))

Was not quite how I expected it to play lol however .... blimey!!!
The delivery aspect has got me all gobsmacked ... we knew about it from research being carried out but for them to have nailed it and to be going with it is to me.... amazing and once again shows what a team science we have...

'Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases.'

Talk about moving away from electroporation!.... The potential here from the whole Covidity package is absolutely immense...

indeed watch this space because many others will be watching this science its value is hard to overestimate!

As for sp reaction ... there is that missing commercial element I'm not too bothered it will come plus we could yet get another SKY effect... 'So prof Durrant can you also whip up a version targeting the Delta variant' 'Sure with funding no problem' :)

The important thing for me is this science of covidity has and is being waved under some very capable noses that have the ability to take the product all the way ... CEPI we can be sure are aware and maybe very close and BioNTech we know ....no doubts there are others too...but something needs to give this program needs to rapidly become a clinical realty the need is still very real .....it's got to get interesting soon ....trial in weeks turned out to be pie in the SKY but the science has not slept and the product is here to be utilised...

' These data support the translation of this DNA vaccine platform into the clinic, thereby offering a particular advantage for targeting emerging SARS-CoV-2 variants.'

More interesting is the author of CEPI article likes to retweet it on her Twitter feed and prof Ball has retweeted not her article but one of her tweets which does indicate a possible relationship between CEPI and team notts anyways till we know we don't but a partnership there would not surprise me just would like it to be announced already:)

As you might expect has taken a right sp kicking due to its CV19 vax not proving to be a of practical use (bit of a bounce-back today).... the thing is the company still has an mcap of nearly £12 billion! yet its pipeline mostly relies on the tech that has failed in CV19... speculation being their way of using 'un modified' RNA instead of how BioNTech and moderna use modified RNA has proven to be a mistake as it probably breaks down too soon to be of use inside cells.... I know I'd not want to be invested in it now... much better to have a broader pipeline and with ImmunoBody already shown to induce immune response I think the scancell way is looking promising so lets be having our chance via trial already! :)

You're reading it wrong...

'The Scientific Advisory Committee is an independent advisory body that provides scientific support, advice, and guidance to CEPI staff and the CEPI Board. Final decision-making about the issues addressed by the committee rests with CEPI staff or the CEPI Board.'

I bet it goes down to £7.95 on no news

Just means having a bus pass :)

I hope all the new staff get along... Cliff having to head over to the labs every week to intervene in testube throwing fights :)

Brilliant brilliant news though and significant progress ..... It is part of what Redmiles intervention funding was all about to get this company from just being brilliant research and for it actually have products saving lives and getting to market....onwards

I guess it could help explain that continnum tweet :

Continuum Life Sciences
@ContinuumLS
·
14 Feb
Congratulations to Professor Lindy Durrant&her Scancell team. Professor Durrant is part of our dedicated&valued Nottingham University team researching our unique long term cancer survivors. Exciting developments expected soon.
So proud.'

Well done Bermuda for distracting RG away from his tomatoes with that great article tweet :)

potting shed could soon be boiling over! red dots everywhere

Indeedy:

'Continuum will develop novel treatments for cancer by researching the cells and molecules that have enabled long-term cancer survivors to stay alive



Continuum Life Sciences has made considerable progress over the last couple of years in the identification of mechanisms behind long-term cancer survival. The company is now embarking on the next phase of development with the building of its own R&D facility in Oxfordshire, UK. To support our expanding activities we are looking for the following new colleagues to join our dynamic and enthusiastic team. '

https://jobs.newscientist.com/en-gb/job/1401731952/research-and-development-manager-/

C11 of course they all count lol....

Ray I bet though not retirement % that the 12% rise helped make his return to work feel a bit better :)

RNS every day this week then! (so far) :)

Nice to have a buzz again and let's hope there is big coming newsflow behind it.... noticed the Boerse nibbler had a few again too.

Could turn out right with the shotgun approach an RNS every day this week lol.... Ruck'll work out the odds :)

I agree it's positive to see modi 1 still looking like getting into trial H1 ... although it could also be they always attach the same bumf at bottom of RNS's and have just copied and pasted as usual... if that is the case and modi 1 trial is slipping into h2 then poor form who ever proof reads and green lights the RNS.... so here is hoping everything is on track ... And err c11's RNS tommo :)

Roses yeah so someone else taking tastey bites BTW well done all those that thought there was another wiggle on its way.... I have no idea what it means apart from they know more than us and they will only be buying because they believe they will make a (substantial) profit above 20p

Crikey so it was the foxy Digs... another Diggle wiggle! Not exactly the RNS/s we all want however not a bad one either but what does it mean for newsflow?... hmm I suppose as far as CEPI goes that is very much in their hands if indeed scancell applied then everyone hears at the same time if Covidity is successful in being chosen or not so would not suppose it would be classed insider dealing...but I dunno lol anyways we got a Monday RNS

Meaning ...no buyout will be possible until results...And likelihood on good results is partnerships....
Or condensed down Lindy knows the worth of her techs and will never sell them short.....i,e we have IPs worth as much as BioNTechs etc and Lindy like Sahin will never give her babies away

I'm not forgetting it and hope scancell don't either...
In my honest opinion we will get news exactly when... no idea but am willing to bet this month is it... exactly what news I don't know either but I reckon it will be big.....
I do not see is as a buy out myself and yes even on results I reckon Lindy has seen what BioNTech has achieved and thought to herself..... hmmmmmmmmmm......Yes all about results and an ability to get partnerships.

Not anything in it but Prof Ball retweeted a tweet by the young lady who wrote the CEPI article we are included in their head of Comms or something.... possible indication of relationship or of nothing more than pro vaxing support

New therapeutics, vaccines and diagnostics against potential future pathogens should be part-developed before the next pandemic starts, involving sustained innovation and collaboration between large and small companies, academic and medical researchers, regulators and global health bodies